Beryl Drugs Ltd

Transaction details

• Target: Beryl Drugs Limited (ISIN INE415H01017).
• Acquirer: Mr. Sudhir Sethi (Promoter); no PAC details disclosed.
• Acquirer belongs to promoter/promoter group.
• Listed on: BSE Ltd.
• Pre-acquisition holding: 514,119 shares, 10.14% voting rights.
• Acquired 4,809 shares (0.10%) via market transactions.
• Post-acquisition holding: 518,928 shares, 10.24%.
• Mode: Market transactions (open market).
• Date of acquisition: 18-08-2026.
• Equity share capital/voting capital before and after: 50,71,700 shares (unchanged).
• Salient features: Equity shares; no conversion or redemption features specified.

Acquisition under Reg. 29(2)

• Target Company: Beryl Drugs Limited.
• Disclosing Party: Mr. Sudhir Sethi, promoter of Beryl Drugs Limited.
• Transaction Type: Acquisition of 3,000 shares (0.06%).
• Pre-Transaction Holding: 511,119 shares, 10.08% of voting capital.
• Transaction Details: 3,000 shares acquired via Market Transactions; equity shares.
• Mode of transaction: Market Transactions.
• Post-Transaction Holding: 514,119 shares, 10.14% of voting capital.
• Date of Transaction: 17-08-2026.
• Equity share capital before: 50,71,700.
• Equity share capital after: 50,71,700.
• Total diluted share capital after: 50,71,700.

Financial highlights

• Total revenue from operations (net): 756.63 Lakh for quarter ended 30/06/2026.
• Profit before tax: 26.98 Lakh; tax expense: 4.90 Lakh.
• Net profit for the period: 22.08 Lakh.
• Total comprehensive income: 22.76 Lakh; other comprehensive income: 0.68 Lakh.
• Earnings per share (continuing operations): Basic 0.47; Diluted 0.30.
• Exceptional items: 0.00.
• Revenue from operations is net of GST.
• Unaudited quarterly results.

Operating segment

• Single operating segment: Pharmaceutical Industry.

Financial results and accounting

• Unaudited financial results for quarter ended 30 June 2026 approved.
• Limited Review Report from auditors for quarter ended 30 June 2026 taken on record.
• Books of accounts to be kept at 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore.

Meeting Details

• Date: 11 August 2026; Time: 02:00 PM; Location: Bicholi, Indore (M.P.) 452016.

Key Agenda Items

• Unaudited financial results for quarter ended 30 June 2026.
• Adopt and approve Limited Review Report for quarter ended 30 June 2026.
• Any other matter with permission of chair.

Other Notes

• Trading window closed from 1 July 2026; to reopen after 48 hours.

Dematerialisation/rematerialisation status

• Dematerialisation requests received during the quarter were processed and confirmed (accepted/rejected) to the depositories.
• Securities dematerialised have been listed on the stock exchanges where the existing securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled; depository's name substituted as registered owner within 15 days.

Non-convertible securities status

• No non-convertible securities outstanding; no payments due or unpaid during the quarter.

Beryl Drugs Ltd — Trading window closed from 15 July 2026 until 48 hours after declaration of unaudited results for quarter ended 30 June 2026